117 related articles for article (PubMed ID: 1527701)
1. Autoimmune kidney disease in MRL/lpr mice inhibited by OK-432; II. Effect of indomethacin.
Mihara M; Ohsugi Y
J Pharmacobiodyn; 1992 May; 15(5):255-9. PubMed ID: 1527701
[TBL] [Abstract][Full Text] [Related]
2. The biological response modifier OK-432 (a streptococcal preparation) inhibits the development of autoimmune kidney disease in NZB/W F1 hybrid mice: possible involvement of tumor necrosis factor.
Mihara M; Ohsugi Y
Int Arch Allergy Appl Immunol; 1989; 90(1):37-42. PubMed ID: 2807578
[TBL] [Abstract][Full Text] [Related]
3. Autoimmune kidney disease in MRL/Mp-lpr/lpr mice inhibited by OK-432, a streptococcal preparation.
Mihara M; Ohsugi Y
Clin Exp Immunol; 1989 Oct; 78(1):102-7. PubMed ID: 2805413
[TBL] [Abstract][Full Text] [Related]
4. Effects of early and late treatment with anti-CD4 monoclonal antibody on autoimmune disease in MRL/MP-lpr/lpr mice.
Jabs DA; Kuppers RC; Saboori AM; Burek CL; Enger C; Lee B; Prendergast RA
Cell Immunol; 1994 Mar; 154(1):66-76. PubMed ID: 7907009
[TBL] [Abstract][Full Text] [Related]
5. IFN-gamma receptor signaling is essential for the initiation, acceleration, and destruction of autoimmune kidney disease in MRL-Fas(lpr) mice.
Schwarting A; Wada T; Kinoshita K; Tesch G; Kelley VR
J Immunol; 1998 Jul; 161(1):494-503. PubMed ID: 9647261
[TBL] [Abstract][Full Text] [Related]
6. Stimulation of arachidonic acid metabolism by a streptococcal preparation (OK-432) in rat peritoneal macrophages.
Watanabe M; Shishido Y; Hirasawa N; Mue S; Fujiki H; Ohuchi K
Biochim Biophys Acta; 1992 Feb; 1138(2):157-61. PubMed ID: 1540662
[TBL] [Abstract][Full Text] [Related]
7. Protection against autoimmune nephritis in MyD88-deficient MRL/lpr mice.
Sadanaga A; Nakashima H; Akahoshi M; Masutani K; Miyake K; Igawa T; Sugiyama N; Niiro H; Harada M
Arthritis Rheum; 2007 May; 56(5):1618-28. PubMed ID: 17469144
[TBL] [Abstract][Full Text] [Related]
8. Effect of several kinds of drugs on the development of autoimmunity in MRL/Mp-lpr/lpr mice; lack of correlation between the suppression of autoantibody production and prevention of autoimmune disease.
Mihara M; Ohsugi Y
J Pharmacobiodyn; 1989 Feb; 12(2):100-6. PubMed ID: 2526211
[TBL] [Abstract][Full Text] [Related]
9. Nrf2 deficiency improves autoimmune nephritis caused by the fas mutation lpr.
Morito N; Yoh K; Hirayama A; Itoh K; Nose M; Koyama A; Yamamoto M; Takahashi S
Kidney Int; 2004 May; 65(5):1703-13. PubMed ID: 15086909
[TBL] [Abstract][Full Text] [Related]
10. Nephritogenicity of the lprcg gene on the MRL background.
Kimura M; Ogata Y; Shimada K; Wakabayashi T; Onoda H; Katagiri T; Matsuzawa A
Immunology; 1992 Jul; 76(3):498-504. PubMed ID: 1526655
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of superantigen-induced proinflammatory cytokine production and inflammatory arthritis in MRL-lpr/lpr mice by a transcriptional inhibitor of TNF-alpha.
Edwards CK; Zhou T; Zhang J; Baker TJ; De M; Long RE; Borcherding DR; Bowlin TL; Bluethmann H; Mountz JD
J Immunol; 1996 Aug; 157(4):1758-72. PubMed ID: 8759766
[TBL] [Abstract][Full Text] [Related]
12. Fc receptor-independent development of autoimmune glomerulonephritis in lupus-prone MRL/lpr mice.
Matsumoto K; Watanabe N; Akikusa B; Kurasawa K; Matsumura R; Saito Y; Iwamoto I; Saito T
Arthritis Rheum; 2003 Feb; 48(2):486-94. PubMed ID: 12571859
[TBL] [Abstract][Full Text] [Related]
13. Effects of castration and sex hormones on immune clearance and autoimmune disease in MRL/Mp-lpr/lpr and MRL/Mp-+/+ mice.
Shear HL; Wofsy D; Talal N
Clin Immunol Immunopathol; 1983 Mar; 26(3):361-9. PubMed ID: 6872348
[TBL] [Abstract][Full Text] [Related]
14. An immunomodulating anti-rheumatic drug, lobenzarit disodium (CCA): inhibition of polyclonal B-cell activation and prevention of autoimmune disease in MRL/Mp-lpr/lpr mice.
Mihara M; Nakano T; Ohsugi Y
Clin Immunol Immunopathol; 1987 Dec; 45(3):366-74. PubMed ID: 3500002
[TBL] [Abstract][Full Text] [Related]
15. A novel antifolate, MX-68, inhibits the development of autoimmune disease in MRL/lpr mice.
Mihara M; Takagi N; Urakawa K; Moriya Y; Takeda Y
Int Arch Allergy Immunol; 1997 Aug; 113(4):454-9. PubMed ID: 9250591
[TBL] [Abstract][Full Text] [Related]
16. Spontaneous autoimmune skin lesions of MRL/n mice: autoimmune disease-prone genetic background in relation to Fas-defect MRL/1pr mice.
Furukawa F; Kanauchi H; Wakita H; Tokura Y; Tachibana T; Horiguchi Y; Imamura S; Ozaki S; Takigawa M
J Invest Dermatol; 1996 Jul; 107(1):95-100. PubMed ID: 8752846
[TBL] [Abstract][Full Text] [Related]
17. Release of tumor necrosis factor (TNF) into mouse peritoneal fluids by OK-432, a streptococcal preparation.
Yamamoto A; Nagamuta M; Usami H; Sugawara Y; Watanabe N; Niitsu Y; Urushizaki I
Immunopharmacology; 1986 Apr; 11(2):79-86. PubMed ID: 3710767
[TBL] [Abstract][Full Text] [Related]
18. The role of interleukin 12 and nitric oxide in the development of spontaneous autoimmune disease in MRL/MP-lpr/lpr mice.
Huang FP; Feng GJ; Lindop G; Stott DI; Liew FY
J Exp Med; 1996 Apr; 183(4):1447-59. PubMed ID: 8666903
[TBL] [Abstract][Full Text] [Related]
19. TNF-alpha enhances colony-stimulating factor-1-induced macrophage accumulation in autoimmune renal disease.
Moore KJ; Yeh K; Naito T; Kelley VR
J Immunol; 1996 Jul; 157(1):427-32. PubMed ID: 8683148
[TBL] [Abstract][Full Text] [Related]
20. Effect of methotrexate treatment on the onset of autoimmune kidney disease in lupus mice.
Mihara M; Katsume A; Takeda Y
Chem Pharm Bull (Tokyo); 1992 Aug; 40(8):2177-81. PubMed ID: 1423777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
